Alt image -https://content.stockstotrade.com/wp-content/uploads/2026/10/orthopediatrics-jumps-4-after-device-clearance.webp

OrthoPediatrics Climbs 6% After Raising Guidance

TIM BOHEN•UPDATED OCT. 27, 2026, 8:44 PM ET
Reviewed by Jack Kelloggand Fact-checked by Ben Sturgill

OrthoPediatrics rose 6% after hours after raising its outlook and reporting record quarterly revenue growth.

KIDS Candlestick Chart

Get Free Alerts

Why OrthoPediatrics Stock Jumped 6% After Hours

OrthoPediatrics Corp. (NASDAQ: KIDS) is up 6% after hours at $25.49 after reporting quarterly results and raising its financial guidance, management’s forecast for future results. Revenue reached $72.7 million, up 19% from a year earlier, showing sales growth behind the higher outlook. Trading totaled about 380,000 shares, a bit above the usual pace.

What OrthoPediatrics Corp. Does

The company sells orthopedic implants and tools designed for children’s bones. Its more than 95 systems support care for bone injuries, deformities, scoliosis, a sideways curve of the spine, and sports injuries. Focusing on children lets the company build products around growing bodies rather than relying only on devices made for adults.

OrthoPediatrics Q3 Sales Growth

Sales rose in both U.S. and international markets, while the company’s trauma and deformity and scoliosis businesses also grew. Growth across these areas suggests the quarter was not driven by just one product category.

Quick Financial Overview

OrthoPediatrics has growing sales and a positive profit measure that leaves out some costs. It held $45.9M in cash, cash equivalents, and short-term investments as of June 30, 2026, which includes bank money and investments that can be turned into cash. That balance predates the latest results.

OrthoPediatrics Adjusted EBITDA and Cash Flow

Adjusted EBITDA, a company-defined profit measure that excludes certain costs and adjustments, was $6.9 million, compared with $6.2 million a year earlier. Free cash flow, cash remaining after operating cash flow is reduced by capital spending, was $1.6 million, a $5.0 million improvement from a year earlier. That improvement means more cash remained after operating needs and investment in the business.

OrthoPediatrics Profit Measure Limits

Adjusted EBITDA does not include every expense, so it is not the same as net income.

Get Free Alerts

OrthoPediatrics Nears Its 52-week High

OrthoPediatrics shares are up 57% from the low $15s over six months, leaving them near the top of their yearly range. That puts the stock close to its yearly peak rather than at the start of a recovery from a recent low.

OrthoPediatrics Femur Nail Clearance

The U.S. Food and Drug Administration cleared the company’s Femur Retrograde Nail System for sale, and surgeons have completed the first procedures with it. The system is part of the Pediatric Nailing Platform, a group of surgical nails designed for children’s bones. A limited market release is planned for the rest of this year, ahead of broader distribution in 2027.

Get Free Alerts

Conclusion

Next year’s broader rollout will test whether surgeon use turns into lasting product sales. Wider adoption would show whether it can add to the business, while a slow rollout would leave that case unproven.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.


The Game is Rigged

But Our AI-driven analysis Has Leveled the Playing Field

Sign up for access to institutional grade tools and insights – and join 10,000+ traders